Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761897 | 1.00 | SLC6A2 (0.40) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL3761494 | 1.00 | SLC6A2 (0.40) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL29502202 | 1.00 | SLC6A2 (0.40) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL3761366 | 1.00 | SLC6A2 (0.40) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL3760879 | 1.00 | SLC6A2 (0.40) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL25244697 | 1.00 | SLC6A2 (0.40) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL3765578 | 1.00 | SLC6A2 (0.40) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL12216729 | 0.82 | ABCB1 (0.42) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL2739937 | 0.82 | ABCB1 (0.42) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 | |
| SCHEMBL9786879 | 0.79 | SLC6A2 (0.38) | SLC6A2CYP2D6SLC6A4LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759584-B2 | Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates | BAYER CROPSCIENCE AG (DE) | 2014-06-24 | — | — | US | disclosed |
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2070934-A1 | Synthesis of biguanidines and triazines, and biguanidino-aluminium complexes as intermediates | Bayer CropScience AG (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305317-A1 | SYNTHESIS OF BIGUANIDINES AND TRIAZINES, AND BIGUANIDINO-ALUMINIUM COMPLEXES AS INTERMEDIATES | ATIC, SRM, F12 | SLC6A2 1543/4885CYP2D6 3643/4885SLC6A4 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.